Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vobarilizumab in Moderate to Severe Active SLE
NCT02437890Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of vobarilizumab in systemic lupus erythematosus (SLE), sponsored by Sanofi. Started Jul 2015; status: completed.
02
Drugs
vobarilizumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02437890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437890.